Together, we can help make healthcare work better for everyone
Our Clinical Research team partners with scientists to make clinical research trials safe and easy to participate in.
Coronavirus
Services
More
Carbon Health is a nationwide, outpatient primary and urgent care provider dedicated to increasing access to high-quality care. As part of this mission, Carbon for Research (C4R) seamlessly integrates clinical trials into every day patient care, shaping a future of medicine that works for everyone.
Across our 80+ owned and operated locations across the country, we meet patients in their communities. Our centers conduct end-to-end studies, refer patients seeking care in real time, and coordinate trial operations across multiple geographies all led by experienced researchers from leading AMCs.
Meet our research leaders
Aaron Weinberg, MD
VP of Medical for
Clinical Research
Clinical Research
Niree Hindoyan
Director of Operations
for Clinical Research
for Clinical Research
Christina Solomon
Head of Strategy
What makes us different
10+ Therapeutic Areas
with a focus on common
conditions that impact a
general medicine population
with a focus on common
conditions that impact a
general medicine population
Acute care conditions
Cardiovascular
Dermatology
Devices
Diagnostic
Vaccines
Cardiovascular
Dermatology
Devices
Diagnostic
Vaccines
General internal medicine
Infectious diseases
Metabolic
Obesity medicine
Respiratory
... & more
Infectious diseases
Metabolic
Obesity medicine
Respiratory
... & more
56% more diverse
Our trial participants are more likely to be non-white than FDA averages. Also, 97% of our participants are new to clinical research.
80+ locations in
8 states
8 states
We conduct research at sites where 1M+ patients already seek care, complementing research with the capabilities of a community-based healthcare provider
Startup < 1 month
Our central research team streamlines your processes. One point of contact, one budget, one contract for our full network. Coordinated startup and ongoing operations across the geographies throughout the entire trial invites easy scalability. Multi-tiered systems to ensure the highest quality patient safety and data
Our partners include:
Our trials in the journals
A phase 3 randomized, double-blind clinical study to evaluate the safety and immunogenicity of V116 when administered concomitantly with influenza vaccine in adults 50 years of age or older (link)
VACCINE. 25 JULY 2025.
Immunogenicity and Safety of Influenza and COVID-19 Multicomponent Vaccine in Adults ≥50 Years (link)
JAMA. 7 May 2025.
Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age (link)*
MDPI. 15 February 2025.
Clinical performance of Abbott ID NOW™ COVID-19 2.0 rapid molecular point-of-care test compared to three real-time RT-PCR assays (link)*
ASM (American Society for Microbiology) journal. 11 february 2025.
Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial (link)*
Clinical infectious diseases. 19 july 2023.
Browse a few of our current trials
Click on the buttons for more info ABOUT EACH STUDY
Where do we conduct research?
With 90+ locations nationwide, we recruit volunteers who reflect real communities. Some sites serve as research hubs, supporting
nearby locations.
Services
Company
For Business
Get in touch
